Iovance provides updates on Amtagvi (lifileucel)
In its latest (Q2) earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs due to lower… read more.
In its latest (Q2) earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs due to lower… read more.
Idorsia announced that The Galien Foundation, a premier global institution dedicated to honoring innovators in life sciences, has nominated Tryvio (aprocitentan) in the category of “Best Pharmaceutical Product”… read more.
University of Georgia researchers have developed a new type of hand sanitizer that eliminates more than 97% of bacteria and fungi, including antibiotic-resistant strains. The new gel provides an alternative… read more.
Researchers report that treating complicated Staphylococcus aureus bloodstream infections with two intravenous (IV) doses of the antibiotic dalbavancin seven days apart is as effective as treatment with daily… read more.
Use of the diabetes drug metformin appears to be linked to reduced risk of dementia and death in obese patients, researchers reported on August 6, 2025 in Diabetes,… read more.
UCB announced that it has received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for at-home self-administration with infusion pump or a new manual push… read more.
The EMA revealed that Pfizer had withdrawn its application submitted on December 20, 2024, for variation to the marketing authorisation for Ngenla to treat adults with growth hormone… read more.
Low-dose (5mg) olanzapine reduces chemo-induced nausea in breast cancer patients without causing sedation, researchers reported on July 1, 2025 in The Lancet Oncology. As background for this study,… read more.
Ivermectin administered to the whole population significantly reduces malaria transmission, offering new hope in the fight against the disease. The BOHEMIA trial, the largest study on ivermectin for malaria… read more.
Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in Europe commercially available in an autoinjector. Developed and registered by Samsung… read more.
An international study led by researchers at the University of Colorado Anschutz Medical Campus has identified a promising strategy to enhance the safety of nanomedicines, advanced therapies often used in… read more.
Celltrion announced that the FDA has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to Actemra. Avtozma is indicated for… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.